Filing Flows › Comparisons › AMGN vs GILD
Amgen vs Gilead Sciences: AMGN and GILD compared
Amgen is the larger company: $10.4B of revenue in its latest quarter (Q3 2026) against $8.3B for Gilead Sciences (Q3 2026). Amgen is growing faster (+8% against +7% a year earlier). Gilead Sciences is more profitable, with an operating margin of 41.7% against 35.8%.
Where the money goes: AMGN and GILD
Amgen (AMGN) · Q3 2026
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
Gilead Sciences (GILD) · Q3 2026
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
| Amgen (AMGN) | Gilead Sciences (GILD) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.4B | $8.3B |
| Revenue growth, Y/Y | +8% | +7% |
| Operating margin | 35.8% | 41.7% |
| Net earnings | $3.9B | $2.4B |
| Net margin | 37.3% | 29.3% |
| Operating cash flow | $4.2B | $5.0B |
| Free cash flow | $3.7B | $4.8B |
| Market value | $251.3B | $209.6B |
| P/E | 26.7× | — |
| Analysts’ mean target | $429.74 | $174.77 |
Where the revenue comes from
Amgen
- Product sales: $9.9B (95%)
- BLINCYTO: $496M (5%)
Gilead Sciences
- Total HIV: $6.3B (76%)
- Trodelvy: $506M (6%)
- Total Cell Therapy: $355M (4%)
- Genvoya: $339M (4%)
Questions
Which is bigger, Amgen or Gilead Sciences?
Amgen is the larger company: $10.4B of revenue in its latest quarter (Q3 2026) against $8.3B for Gilead Sciences (Q3 2026).
Is Amgen or Gilead Sciences growing faster?
Amgen is growing faster (+8% against +7% a year earlier).
Which is more profitable, Amgen or Gilead Sciences?
Gilead Sciences is more profitable, with an operating margin of 41.7% against 35.8%.
More: Amgen earnings · how Amgen makes money · Gilead Sciences earnings · how Gilead Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.